PPT-EGFR-Mutated NSCLC and CNS Involvement: the Conundrum

This program will include a discussion of offlabel treatment and investigational agents not approved by the FDA for use in the US and data that were presented in abstract form These data should be considered preliminary until published in a peerreviewed journal. Gandara. , MD. University of California, Davis . Comprehensive Cancer Center. Biomarker-driven Phase III Clinical Trials: . Practical . & . Design Considerations. Clinical trial . d. esigns that define the. Le Chevalier, . MD. The Role of Translational Research . in . NSCLC. Outline of Talk. The importance of translational research in improving treatment of NSCLC. Key remaining unmet needs. Overview of promising approaches/agents in the future treatment of NSCLC . Nathan Pennell, M.D., Ph.D.. September 6, 2014. Objectives. Discuss the role of chemotherapy in molecularly defined populations. Discuss the addition of chemo and/or bevacizumab (Avastin) to targeted therapy. attraverso . i . c. asi clinici. Giuseppe . Valmadre. Claudia . Maggioni. NSCLC ALGORITMO TERAPEUTICO. Generale. 1 .ADENOCARCINOMA 1 linea. Mutazione EGFR o . Traslocazione. ALK positivo. Mutazione EGFR o . MD. The Evolving Treatment Landscape in NSCLC: Congress Updates. Outline of Talk. Provide a brief overview of current advances in the treatment of NSCLC. EGFR-targeted agents . ALK-EML4 targeted agents . The Coming Paradigm Shift. Faculty. Suresh S. Ramalingam, MD. Professor of Hematology/Oncology . Director, Lung . Cancer Program . Winship Cancer Institute. Emory University. Atlanta, . Georgia. Program Goals. actual. . video-recorded proceedings from the . live . CME event and may include the use of trade names and other raw, unedited content. . Disclosures for . Dr. Langer. Advisory Committee. Abbott Laboratories, AstraZeneca Pharmaceuticals LP, . proceedings from the live CME event and may include . the use of trade names and other raw, unedited content. . Moderator. Neil Love, MD. Faculty . Oncology Grand Rounds. . Emerging Strategies in Non-Small Cell Lung Cancer. Consequences of the Lack of Patients of color & Structural barriers to Quality. Christopher S. Lathan, M.D., M.S., M.P.H. Assistant Professor of Medicine. Faculty Director of Cancer Care Equity, Dana-Farber Cancer Institute. Prediction. . and. . Data Sorting. Zhengtao. Li/06-24-2019. Introduction. https://www.ppdi.com/About/About-Drug-Discovery-and-Development. What . medchem. should focus?. IP. Target engagement. ADME property. Abramson Cancer Center . University of Pennsylvania. Philadelphia, Pennsylvania. Keeping Up in NSCLC: Actionable Biomarkers and Their Impact on Treatment. Rasheda Persinger, MSN, AGNP-C, AOCNP. Lead Nurse Practitioner. Kamil Konopka. Department of Oncology, University Hospital in Cracow. Lung cancer epidemiology. Most common malignancy worldwide. 14% of all new cancers are lung cancers. Lung cancer (NSCLC&SCLC) is the second most common cancer in both men and women (excluding skin cancers). Ana Rima. PENDAHULUAN. 2. Kanker Paru. P. enyebab . utama kematian akibat kanker . . Terdiagnosis pada stadium lanjut. Pembagian pasien kanker paru berdasarkan stadium di bangsal paru RSDM. Th. 2014 . Professor Rachel Butler. The genomic complexity of advanced NSCLC. Jordan et al. Cancer Discovery (2017). >50% NSCLC now have actionable variant. Treatment algorithm. NHSE: National Genomic Test Directory.